Elevated tumour marker CA19-9: Clinical interpretation and influence of obstructive jaundice

European Journal of Surgical Oncology

Volumn 26, Issue 5, 2000, Pages 474-479

  Mann, D V ^b   Edwards, R ^a   Ho, S ^b   Lau, W Y ^b   Glazer, G ^a,c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NONE   (United Kingdom)

Author keywords

Obstructive jaundice; Pancreatobiliary malignancy; Tumour marker

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BILIRUBIN BLOOD LEVEL; CHRONIC PANCREATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; FOLLOW UP; GALLSTONE; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; MAJOR CLINICAL STUDY; OBSTRUCTIVE JAUNDICE; PANCREAS CARCINOMA; PRIORITY JOURNAL;

EID: 0033830039     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1999.0925     Document Type: Article

References (25)

1. Gastrointestinal cancer-associated antigen in immunoperoxidase assay
2. The clinical utility of the CA19-9 tumour-associated antigen
3. CA19-9 in non-neoplastic liver diseases: A clinical and laboratory study
4. Serum increase and liver overexpression of carbohydrate 19-9 antigen in patients with genetic haemochromatosis
5. Elevated serum levels of tumour marker CA19-9 in acute cholangitis
6. Markedly elevated CA19-9 levels in a case of chronic pancreatitis
7. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease
8. Initial clinical evaluation of an immunoradiometric assay for CA19-9 using the NCI serum bank
9. The evaluation of CA19-9 antigen level in the early detection of pancreatic cancer
10. Comparison of a new tumour marker, CA19-9, with alphafetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases
11. Colorectal carcinoma antigens detected by hybridoma antibodies
12. New carbohydrate tumor markers
13. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin
14. Tumour markers in pancreatic cancer: Sensitivity and specificity of CA19-9
15. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas
16. Tumour marker antigen CA125 in pancreatic cancer: A comparison with CA19-9 and CEA
17. CA19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis
18. CA19-9 and CA50 in benign and malignant pancreatic biliary diseases
19. Hepatic clearance of serum glycoproteins
20. Pathophysiology of tumour progression in human gallbladder: Flow cytometry, CEA, and CA19-9 levels in bile and serum in different stages of gallbladder disease
21. Serum levels of carbohydrate antigenic determinant (CA19-9) in obstructive jaundice
22. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases
23. CA19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
24. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer
25. Prospective study of CAM17.1/WGA mucin assay for serological diagnosis of pancreatic cancer